Pfanstiehl Sheds Ferro Corp. For Greater Investment & Growth
After operating under the Ferro umbrella for 13 years, Ferro Pfanstiehl Laboratories was purchased by PLI Holdings, an affiliate of Med Opportunity Partners (MEDOP). James Breckenridge, founding member of MEDOP, and Cynthis Kerker, president of Pfanstiehl, discuss why the acquisition is good news for the future growth of Pfanstiehl, and how the company's products, focus on quality, and SafeBridge certification made them a good fit with MEDOPs other strategic partners.
WHITE PAPERS & CASE STUDIES
Streamlining The Biological Factory: Making A Better CHO Cell For Biopharma Production
SAFC’s CHOZN® Platform has been developed as a ‘plug and play’ manufacturing system for the creation of biopharmaceutical producing cell lines.
Save Up To 8 Hours In Cell Line Development With ZFN Technology
Zinc finger nucleases (ZFNs) have proven to be a powerful tool for modifying genes. In comparison to traditional techniques, such as adding chemical or radiation based mutagens that cause various random mutations, ZFNs can create very accurate, targeted changes to the genome in a much more rapid fashion.
Meeting BioPharma Needs For Lower Operating Cost And Faster Time To Market
Broad adoption awaits fully scalable GMP systems, improved and less costly disposables, better analytics, greater process automation and low-shear mixing.
The Next Bioprocessing Revolution: Functional Additives
Now that many bioproduction technologies and processes are reaching maturity, manufacturers are seeking out the next level of refinements. As an extension of successful fed-batch strategies (such as the use of matched media and feeds), the next stage in bioprocess refinement involves the development of highly concentrated functional additives that can be added to each bioreactor run in the smallest amount necessary to give good titer increases.
PRODUCTS & SERVICESMore Products & Services
Formulation in bioresearch is directly associated with pharmaceutical research and development. It is the practice of combining different chemical substances that include the active medical drug. This combination of drug and chemicals is tweaked until they have a final medicinal formulation that can be tested and receive final approval for large-scale market use.
The object of pre-formulation and formulation is to develop a stable preparation of a specific drug that is acceptable for human consumption. All drugs, by necessity, contain other chemicals. In order to put a drug into a capsule or tablet form it requires a variety of substances other than the drug itself. Formulation is needed to ensure that the drug will work when combined with these other substances.
It may surprise you to know that most formulations are not complete until after Phase III clinical trials are in progress or completed. All the early trials test drug stability, and drug load, which is the ratio of active drug to the total content of the actual dose.
Formulation studies address a variety of issues includinggrain size, pH (acidic or alkaline), solubility, and polymorphism (the ability of a drug to exist in more than one form like liquid and capsule). Other items formulation addresses is taste, appearance, tablet hardness and tablet or capsule disintegration.
Another aspect of formulation is testing how humidity, temperature, oxidation, ultraviolet light or visible light affects the formulation. The formula must be stable and not degrade under all of the different environmental factors.
Formulation involves a lot of experimenting with different blends of materials and drugs, but is absolutely crucial for the development of effective, safe, stable, oral drugs, and topical ointments.